William Ho joined New Leaf in January 2011 as a Public Investment Director. Prior to joining NLV, Will was the senior healthcare strategist on a derivatives desk of ICAP plc, the London based broker-dealer. He joined the company from Bank of America, where he was the senior research analyst covering the biotechnology industry. Previously he was also at Piper Jaffray & Co. where he was a research analyst covering the biotechnology and life sciences tools sectors. Will entered equity research from an operational role at CuraGen Corporation, a genomics era biopharmaceutical company where he was responsible for financial and operational analysis including the operating budget and several of the company’s restructurings. Earlier in his career, Will was an associate in the health care investment banking group at SG Cowen. In 2008, Will was named the "Best Up-and-Comer" in the biotechnology sector by Institutional Investor in its All-America Research Team rankings.

Will received a master of business administration degree from the University of Notre Dame and a bachelor of science degree in biochemistry, with honors, from McMaster University in Canada.